GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

31Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

This study was conducted to evaluate the effectiveness and tolerance of GDP (gemcitabine, dexamethasone, and cisplatin) regimen in patients with newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKTL). The study enrolled 41 ENKTL patients who received GDP regimen at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 2008 and January 2015. The disease status was newly diagnosed stage IV in 15 patients and relapsed/refractory in 26 patients. The median number of cycles of chemotherapy per patient was 6 (range, 2-8 cycles). The overall response rate and complete-remission rate were 83.0% (34/41) and 41.5% (17/41), respectively. After a median follow-up of 16.2 months, 1-year progression-free survival rate and 1-year overall survival rate for the whole cohort were 54.5% and 72.7%. Grade 3 to 4 adverse events included neutropenia (34.1%), thrombocytopenia (19.5%), and anemia (14.6%). Our study has suggested high efficacy and low toxicity profile of GDP regimen in patients with newly diagnosed stage IV and relapsed/refractory ENKTL.

References Powered by Scopus

Revised response criteria for malignant lymphoma

4113Citations
N/AReaders
Get full text

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas

3373Citations
N/AReaders
Get full text

Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study

555Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type

185Citations
N/AReaders
Get full text

NK-/T-cell lymphomas

95Citations
N/AReaders
Get full text

Extranodal NK/T cell lymphoma

33Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, J. J., Dong, M., He, X. H., Li, Y. X., Wang, W. H., Liu, P., … Shi, Y. K. (2016). GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Medicine (United States), 95(6). https://doi.org/10.1097/MD.0000000000002787

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

60%

Professor / Associate Prof. 2

20%

Researcher 2

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

81%

Biochemistry, Genetics and Molecular Bi... 1

6%

Pharmacology, Toxicology and Pharmaceut... 1

6%

Neuroscience 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0